Evonik ups HPAPI capability in Germany and US as oncology market grows

By Dan Stanton

- Last updated on GMT

Related tags Pharmacology Evonik

Evonik ups HPAPI capability in Germany and US
Evonik ups HPAPI capability in Germany and US
Evonik has upped its capabilities in highly potent active pharmaceutical ingredients (HPAPI) citing the increased market growth of oncology drugs.

“We upgraded our facilities and equipment to be able to provide fomulation services of HPAPIs,”​ Evonik spokesperson Dr. Jürgen Krauter told in-Pharmatechnologist.com

HPAPIs are used mostly in modern oncology drugs,a market that stood at $60bn (€45bn) in 2010 and is – according to a KPMG report​ – expected to grow to around $78bn by 2015. “This makes the oncology drug market highly attractive for us,”​ Krauter said.

Both Evonik’s Darmstadt, Germany, and Birmingham, US facility have seen upgrades in order to handle a range of hormones, peptides and cytostatic agents in both the laboratory and GMP areas. However, Krauter was unable to disclose financial details regarding the expansion.

A number of manufacturers have invested in HPAPIs of late to fulfil increasing demand - including Novasep​, Aesica and Powder Systems Limited​ specifically – though Evonik says there is still a limited number of firms working with these ingredients.

Krauter could not comment on the fim’s competitors but did say Evonik is in a unique position, now offering “the whole value chain from drug substance custom manufacturing, over formulation development and clinical supply down to drug product custom manufacturing” ​for HPAPIs from its facilities.


A number of firms have been investing in antibody-drug conjugates (ADCs) – Roche, Novartis​ and AstraZeneca​ to name some recent Big Pharma entrants - and in order to service this growing segment there has been a spurt of activity on the contract manufacturing side with Lonza​, Baxter​ and Piramel​ examples.

It is the case too for Evonik, with these investments “also related to ADCs and are driven by increased interest in antibody-drug conjugates,” ​an area Evonik is also active in, Krauter told us.

A recent report on contract manufacturing by Frost & Sullivan​ cited cytotoxics “the most significant sources of revenue”​ for the industry within the next five years. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more